Implementing the Medicare $2 drug list model would have reduced out-of-pocket spending by 63% for Part D beneficiaries in 2021. The model caps cost-sharing at $2 for a 30-day supply of 101 generic ...

Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...

The GENEROUS Model aims to reduce Medicaid drug costs by aligning prices with international standards, launching in 2026. It builds on existing programs like the Medicaid Drug Rebate Program and the ...

In the UK, there was a case where TGN1412, an immunotherapy under development, triggered a cytokine storm within hours of administration to humans, leading to multiple organ failure. Another example, ...